|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, July 04, 2015 ) There are no marketed pharmacological therapies that are indicated for DMD. The current standard of care treatment involves generic corticosteroids which are used to marginally prolong muscle function but do not offer preventative treatment.
The anticipated launch of PTC Therapeutics' Translarna in 2015 in the US and 5EU, followed by the 6MM launch of Exon-skipping therapies- BioMarin/Prosensa's drisapersen and Sarepta Therapeutics' eteplirsen, in 2015 and 2016, respectively, are set to change the treatment landscape and drive growth in the DMD market. GlobalData estimates that the uptake of Translarna and exon-skipping therapies will be very high due to the lack of effective disease-modifying therapies for DMD. GlobalData estimates that the DMD market was valued at $8.2m across the 6MM in 2014, and it is expected to sharply increase to approximately $990.0m in 2019, at a Compound Annual Growth Rate (CAGR) of 160.5%.
Request a sample copy this Report at http://www.rnrmarketresearch.com/contacts/request-sample?rname=394090 . (This is a premium report price at US$7995 for a single user PDF license)
Key Questions Answered:
• How will the DMD market landscape change within the 2014-2019 forecast periods in the 6MM
• What are the most promising late-stage pipeline drugs and how will their launch shape the future treatment landscape in the DMD market
• How do the clinical and commercial attributes of late-stage pipeline drugs compare to one another and against existing treatment options
• Which patient population(s) are most likely to be targeted by late-stage pipeline drugs
• What are the significant unmet needs and remaining opportunities in the DMD market
Scope:
• Overview of DMD, including epidemiology, etiology, pathophysiology, symptoms and current treatment options
• Annualized DMD therapeutics market revenue, annual cost of therapies and forecasts for five years to 2019.
• Key topics covered include strategic product assessment, market characterization, unmet needs, R&D strategies, clinical trial design and implications for the DMD therapeutics market.
• Pipeline analysis: comprehensive data split across different phases, emerging trends and mechanisms of action under development, including nonsense mutation readthrough inducer, exon-skipping therapies, synthetic electron transporter, PDE5 inhibitor.
• Analysis of the current and future market competition in the US and five major EU DMD therapeutics market. Clinical and commercial benchmarking of promising pipeline products versus standard of care treatments and competitive assessment of all therapies. Insightful review of the key industry drivers, restraints and challenges.
Inquire for discount on this report at http://www.rnrmarketresearch.com/contacts/discount?rname=394090 . (This is a premium report price at US$7995 for a single user PDF license)
Reasons to Buy:
• Identify the unmet needs and remaining opportunities in the DMD therapeutics market.
• Develop business strategies by understanding the trends shaping and driving the US and five major EU DMD therapeutics market.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Assess the clinical and commercial viability of promising pipeline products.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies.
More reports Pharmaceuticals Market Research Reports:
Global Opioid-Induced Constipation Market 2015-2019
Opioids are administered to the patients with acute and non-cancer chronic pain. They have several adverse gastrointestinal effects, one of which is opioid-induced constipation. The opioid analgesics produce analgesia by the activation of the mu receptors found in the CNS and PNS. These drugs affect the motility, tone, and contractility of the bowel functions, which results in the delay in the transit of fecal contents. The opioids also cause a reduction in the secretion of digestive enzymes and also cause partial gastroparesis.
Complete report is available at http://www.rnrmarketresearch.com/global-opioid-induced-constipation-market-2015-2019-market-report.html .
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
